Synergistic effects: Combining PDE5 inhibitors with checkpoint inhibitors, such as PD-1 inhibitors, may synergistically enhance treatment efficacy in patients with advanced HCC. This evidence concerns the gene PDE5A and hepatocellular carcinoma.